Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of LENZ Therapeutics in a report ...
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on LENZ Therapeutics (LENZ – Research Report), with a ...
Stock analysts at William Blair issued their FY2026 earnings per share estimates for shares of LENZ Therapeutics in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback